How Enhancing Preclinical Analytics Helps Drive Clinical Success

Bioanalysis services are crucial for accelerating biopharmaceutical development. Currently, biopharmaceutical companies have leverage to demand better pricing and service due to automation and increasing competition. While a single CRO offers advantages like cost savings on method validation, specialization often necessitates using multiple partners.

Responding to participant questions after a recent webinar, Dash Bio co-founder and COO Ander Tallett offers insights here on CRO selection and collaboration. He states faster bioanalysis turnaround times enable adaptive preclinical study designs, adding that that AI will likely aid bioanalysis by accelerating report generation and improving existing analytical and translational methods. Tallett also addresses advancing technology, particularly automated CRO platforms, plus fixed-price models for cost control and adaptive trial design.